Clinical Trial Update: LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. [Phase 3]

View source ↗

Summary

LM-302 is being evaluated in a Phase 3 trial for Claudin18.2-positive gastric and gastroesophageal junction adenocarcinoma; the study is currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• LM-302

Snippet

Sponsor: LaNova Medicines Zhejiang Co., Ltd. | Conditions: Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING